Biotech

All Articles

Amgen files 1st phase 3 win for $400M eczema medication

.Amgen has actually shared (PDF) the very first stage 3 records on its $400 million dermatitis medic...

Biogen, UCB report stage 3 lupus win after falling short earlier trial

.Biogen and UCB's gamble on advancing in to phase 3 astride a failed research tries to have paid, al...

Aptadir hopes new RNA inhibitors may reverse challenging cancers cells

.Italian biotech Aptadir Rehabs has introduced with the assurance that its own pipe of preclinical R...

Wave surfs DMD success to regulators' doors, sending stock up

.Surge Life Sciences has met its goal in a Duchenne muscle dystrophy (DMD) study, positioning it to ...

Sanofi plucks new CSO coming from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, using up...

Achilles drops cell therapy plan, bandages for unemployments after missing 'office practicality' targets

.Achilles Rehabs has wrecked its own technique. The British biotech is knocking off on its own clini...

Aligos advertises phase 2 MASH win, reducing liver fat around 46%

.Aligos Rehabs is heralding a midstage succeed in metabolic-dysfunction affiliated steatohepatitis (...

Basilea credit ratings $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's job building new antifungals has actually acquired a considerable increase ...

Capricor offers Europe civil rights to late-stage DMD therapy for $35M

.Possessing presently gathered up the united state civil rights to Capricor Therapies' late-stage Du...

FDA fragments adcomm for Applied's uncommon illness medicine

.After dismissing the decision date for Applied Therapies' metabolic problem drug govorestat, the FD...